Tests subcutaneous tarlatamab in people with small cell lung cancer
Tests subcutaneous tarlatamab for safety in adults with lung cancer.
Plain-language title generated from the registry record
Registry title: Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Key facts
- Where
- Camperdown, Melbourne, and Waratah, AustraliaSee the 3 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with extensive stage small cell lung cancer that came back or got worse after platinum-based treatment. They must be able to have injections under the skin of the abdomen.
- Age
- 18 years or older (or the legal adult age in the country, if that is older than 18).
- Sex
- All sexes can join.
- Disease stage
- Extensive stage small cell lung cancer (ES-SCLC), confirmed by tissue or cell tests, that progressed or recurred after at least one line of platinum-based therapy. ECOG performance status of 0 or 1.
- Earlier treatment
- Must have had at least one line of platinum-based anti-cancer therapy for small cell lung cancer. People treated earlier for limited stage disease must also have had another regimen for the extensive stage disease. Must not have had DLL3 targeted therapy.
Main reasons for not taking part
- Earlier DLL3 targeted therapy
- Untreated or symptomatic brain metastases, or brain metastases needing steroids
- Leptomeningeal disease
- Needing extra oxygen at the start
- Not being able to have injections under the skin of the abdomen
Read by machine on 12 November 2026.
Where in Australia
- Chris Obrien LifehouseCamperdown, AustraliaTaking people
- The Alfred HospitalMelbourne, AustraliaTaking people
- Calvary Mater Newcastle HospitalWaratah, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Amgen
- Trial code
- NCT06598306EU 2024-511838-12-00
- Record updated
- 26 June 2026
- Original description
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.Read full original descriptionShow less
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Inclusion: Participants ≥ 18 years of age (or ≥ legal adult age within country if it is older than 18 years) at time of signing informed consent; Participants with histologically or cytologically confirmed ES-SCLC that progressed or recurred following at least one line of platinum-based anti-cancer therapy for SCLC; Note: Participants with prior treatment for LS-SCLC should have also received another regimen for their recurrent, ES-SCLC disease; Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1; Participants must have adequate organ function (cardiac, pulmonary, kidney, and liver); Participants must be able to have SC injections administered in the abdomen; Participants without measurable disease or tumor tissue (fresh biopsy or archival) available may be permitted after discussion with and approval by Amgen Medical Monitor.
Exclusion: Participants that have received prior DLL3 targeted therapy; Participants with untreated or symptomatic brain metastases or those requiring therapy with steroids; Note: Participants with asymptomatic brain metastatic lesions are allowed following definitive treatment (Amgen Medical Monitor may approve untreated, asymptomatic brain metastasis if local therapy is not required per investigator judgment); Participants with leptomeningeal disease; Participants with baseline oxygen requirement.